CDKN1B and diffuse large B-cell lymphoma: Bortezomib (BTZ) treatment reduces SKP2 via escalation of p27Kip1protein, including XIAP, cIAP1, and survivin, implicating the SKP2/p27Kip1 signaling pathway in DLBCL pathogenesis (78).